Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Christopher Kiff"'
Autor:
James W. Shaw, Bryan Bennett, Katie Noon, Kim Cocks, Christopher Kiff, Andrew Trigg, Madeleine King, Michael DeRosa, Dionysios Ntais, Fiona Taylor
Publikováno v:
Value in Health. 24:1651-1659
Objectives There is growing interest in condition-specific preference measures, including the European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions (QLU-C10D). This research assessed the implica
Autor:
S. Klijn, Murat Kurt, Elisabeth Fenwick, B. Malcolm, Christopher Kiff, Kasper Johannesen, S. Kroep, John Borrill
Publikováno v:
PharmacoEconomics. 39:345-356
The immuno-oncologic (IO) mechanism of action may lead to an overall survival (OS) hazard that changes over time, producing shapes that standard parametric extrapolation methods may struggle to reflect. Furthermore, selection of the most appropriate
Publikováno v:
PharmacoEconomics Open
Objective The aim of this study was to investigate the cost effectiveness of nivolumab versus docetaxel in previously treated, advanced non–small-cell lung cancer (NSCLC) in England and assess how conditional reimbursement within the Cancer Drugs F
Autor:
Robert Carroll, Christopher Kiff, Dara Stein, David Tyas, Delphine Saragoussi, Mira Soni, Ayman Nassar, Nick Maisey
Publikováno v:
Future oncology (London, England). 17(24)
Lay abstract This study looked at the characteristics and quality of life (QoL) of patients who were taking the drug, nivolumab, and how well it works for advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma. GEJ adenocarcinoma is a rare t
Publikováno v:
ClinicoEconomics and Outcomes Research. 11:309-324
Purpose: Cost-effectiveness analyses (CEA) of new technologies typically include “background” costs (eg, all “related” health care costs other than the specific technology under evaluation) as well as drug costs. In oncology, these are often
Publikováno v:
PharmacoEconomics. 38(4)
Mixture modelling is increasingly being considered where a potential cure leads to a long life. Traditional methods use relative survival models for frail populations or cure models that have improper survival functions with theoretical infinite life
Autor:
S. Kroep, Murat Kurt, B. Malcolm, J. Borrill, Elisabeth Fenwick, Christopher Kiff, E. Wu, M. Bianco, C.W. Kraan, S. Klijn, K.M. Johannesen
Publikováno v:
Value in Health. 22:S523-S524
Publikováno v:
Drug discovery today. 24(12)
Real-world data (RWD) generated during the pre-approval phase could be supplementary to primary clinical trial outcomes; however, as we discuss here, a data collection framework is needed to ensure the validity and applicability of these data.
Publikováno v:
Value in Health. 23:S467
Autor:
Cynthia Macahilig, Alicia C. Shillington, Christopher Kiff, FE Cotte, V Dave, P Singh, M Contente
Publikováno v:
Value in Health. 23:S427